Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05806814 · ClinicalTrials.gov registry record · Phase 1
Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer
A Phase 1 study of Metastatic Castration-Resistant Prostate Cancer (mCRPC), sponsored by University of Oklahoma.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT05806814: Recruiting Phase 1 study of Metastatic Castration-Resistant Prostate Cancer (mCRPC), sponsored by University of Oklahoma.
NCT05806814 is a Phase 1 study of Metastatic Castration-Resistant Prostate Cancer (mCRPC) that is actively recruiting participants, run by University of Oklahoma. The registered enrollment target is 13 participants, below the 412-participant average among 15 other Metastatic Castration-Resistant Prostate Cancer (mCRPC) trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05806814, a Phase 1 study of Metastatic Castration-Resistant Prostate Cancer (mCRPC), is actively recruiting participants, sponsored by University of Oklahoma.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
Proposed immunotherapy with an extended course of Sipuleucel-T treatment may induce a more robust immune response and improve the anti-cancer efficacy of Sipuleucel-T in patients with metastatic Castration-Resistant Prostate Cancer (mCRPC).
Primary Outcome
Patients will be treated with Sipuleucel-T immunotherapy and the treatment regimen will be considered feasible if 85% of enrolled patients complete all three infusions of Sipuleucel-T treatment given at week 0, 2 and 12-14.
Conditions Studied
Interventions
- BIOLOGICAL Sipuleucel-T
Study Locations (1)
Oklahoma
- University of Oklahoma Health Sciences Center, Stephenson Cancer Center - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2023-11-12 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
What NCT05806814 shows while recruiting
NCT05806814 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 412-participant average among 15 other Metastatic Castration-Resistant Prostate Cancer (mCRPC) trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Metastatic Castration-Resistant Prostate Cancer (mCRPC) appearing as the primary indexed condition, and to 1 intervention - of which Sipuleucel-T is the first listed.
NCT05806814 reports a single indexed study location in Oklahoma.
Frequently Asked Questions
What is clinical trial NCT05806814 about?
NCT05806814 is a clinical study titled "Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer". Proposed immunotherapy with an extended course of Sipuleucel-T treatment may induce a more robust immune response and improve the anti-cancer efficacy of Sipuleucel-T in patients with metastatic Castration-Resistant Prostate Cancer (mCRPC).
What is the current status of trial NCT05806814?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2023-11-12. Estimated completion is 2026-12.
What conditions does trial NCT05806814 study?
This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC).
What interventions are being tested in trial NCT05806814?
The interventions under investigation include: Sipuleucel-T (BIOLOGICAL).
Who is sponsoring clinical trial NCT05806814?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05806814 being conducted?
This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05806814's enrollment target sits among peer trials
13 15th of 15 higher than 1 of 15 other Metastatic Castration-Resistant Prostate Cancer (mCRPC) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Castration-Resistant Prostate Cancer (mCRPC) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
RECRUITING · Phase 1
-
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
RECRUITING · Phase 1
-
AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)
RECRUITING · Phase 1
-
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
RECRUITING · Phase 1
-
Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients
RECRUITING · Phase 1
-
A Study of NX-1607 in Adults With Advanced Malignancies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI